Multiple Myeloma Clinical Trials in Boston
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Recruiting
- Multiple Myeloma
- Birmingham, Alabama
- +17 more
2022-03-30
Mar 30, 2022J
Recruiting
- Multiple Myeloma
- JNJ-68284528
- +4 more
- San Francisco, California
- +43 more
2022-03-28
Mar 28, 2022K
T
Active, not recruiting
- Multiple Myeloma
- Placebo
- Ixazomib
- Fountain Valley, California
- +277 more
2022-03-23
Mar 23, 2022G
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin frozen liquid
- Belantamab mafodotin lyophilized powder
- New Haven, Connecticut
- +58 more
2022-03-21
Mar 21, 2022P
Active, not recruiting
- Multiple Myeloma
- Lenalidomide
- +3 more
- Birmingham, Alabama
- +45 more
2022-03-29
Mar 29, 2022J
Active, not recruiting
- Multiple Myeloma
- Lenalidomide
- +3 more
- Birmingham, Alabama
- +35 more
2022-03-24
Mar 24, 2022C
Active, not recruiting
- Multiple Myeloma
- bb2121 carfilzomib
- +3 more
- Scottsdale, Arizona
- +18 more
2022-03-23
Mar 23, 2022J
Active, not recruiting
- Multiple Myeloma
- Dara SC
- Dara IV
- Boston, Massachusetts
- +145 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +3 more
- Whittier, California
- +113 more
2022-03-24
Mar 24, 2022J
Recruiting
- Multiple Myeloma
- Bortezomib
- +5 more
- San Francisco, California
- +152 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
- Birmingham, Alabama
- +106 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab IV
- +3 more
- Birmingham, Alabama
- +211 more
2022-03-24
Mar 24, 2022J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
- Multiple Myeloma
- Little Rock, Arkansas
- +56 more
2022-03-24
Mar 24, 2022J
J
Active, not recruiting
- Multiple Myeloma
- Part 1 (Dose Escalation): Daratumumab
- +3 more
- Boston, Massachusetts
- +7 more
2022-03-24
Mar 24, 2022J
Recruiting
- Multiple Myeloma
- Birmingham, Alabama
- +81 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
- Duarte, California
- +21 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
- Little Rock, Arkansas
- +145 more
2022-03-24
Mar 24, 2022D
Recruiting
- Multiple Myeloma
- Sample of Blood
- Baltimore, Maryland
- +2 more
2022-03-22
Mar 22, 2022G
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +5 more
- Atlanta, Georgia
- +41 more
2022-03-23
Mar 23, 2022A
Recruiting
- Refractory Multiple Myeloma
- +2 more
- Ibrutinib
- +2 more
- Maywood, Illinois
- +4 more
2022-03-19
Mar 19, 2022B
No longer available
- Multiple Myeloma
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Concord, California
- +26 more
2022-03-17
Mar 17, 2022D
Active, not recruiting
- Multiple Myeloma
- +3 more
- Boston, MassachusettsDana-Farber Cancer Institute
2022-03-15
Mar 15, 2022A
Active, not recruiting
- Multiple Myeloma
- Dexamethasone
- +3 more
- Aurora, Colorado
- +39 more
2022-03-02
Mar 2, 2022